RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Down 42.3% in March

RemeGen Co., Ltd. (OTCMKTS:REGMF) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 196,500 shares, a drop of 42.3% from the February 28th total of 340,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

RemeGen Stock Performance

OTCMKTS:REGMF opened at $1.50 on Friday. RemeGen has a twelve month low of $1.50 and a twelve month high of $4.00. The stock has a fifty day simple moving average of $1.50 and a 200-day simple moving average of $1.52.

RemeGen Company Profile

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.